
Saturday, May 10, 2025 11:12:32 AM
Interesting news; about 10 months ago, Dr. Missling was directly recruiting for a top level, Head of Neurology position. I had long been curious about what happened to this role and it now looks like Woltgang Liedtke has joined the team in that important position. Dr. Liedtke most recently was the Global Development - Scientific Council:
Chair of Neurology at Regeneron, and is currently a Professor of Neurology at Duke University School of Medicine, as well as a Senior Advisor to the Davos Alzheimer's Collaborative. You might recognize him as having recently made some very supportive comments on both Anavex posts and original posts about blarcamesine on LinkedIn.
This information comes via the attached listing for a seminar he is leading at the 4th Annual ALS Drug Development Summit, May 12-14. I wonder if Anavex is planning on announcing his joining the team either at the
Q2 call this week or sometime around it?
https://www.als-drug-development.com/speaker/wolfgang-liedtk/
http://als-drug-development.com/sp
Looks like Anavex fooled another CNS expert with their scam!

Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2025 09:25:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2025 09:30:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/09/2025 09:30:47 PM
- Anavex Life Sciences to Participate at Upcoming Healthcare Conferences • GlobeNewswire Inc. • 05/14/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2025 08:31:17 PM
- Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/13/2025 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 • GlobeNewswire Inc. • 05/06/2025 11:30:00 AM
- Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 05/01/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2025 12:00:38 AM
- Anavex Life Sciences to Participate in The Citizens Life Sciences Conference • GlobeNewswire Inc. • 04/30/2025 11:30:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/25/2025 08:40:36 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/25/2025 08:35:45 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/25/2025 08:31:01 PM
- Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board • GlobeNewswire Inc. • 04/23/2025 11:30:00 AM
- Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East • GlobeNewswire Inc. • 04/21/2025 11:30:00 AM
- Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease • GlobeNewswire Inc. • 04/05/2025 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:46:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:46:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:45:40 AM
- Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2025 11:30:00 AM
- Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/24/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2025 02:06:26 PM
- Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/12/2025 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 • GlobeNewswire Inc. • 02/05/2025 12:30:00 PM
- Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio • GlobeNewswire Inc. • 01/27/2025 12:30:00 PM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM
VAYK Discloses More Insider Buying Approaching 15 Million • VAYK • Jul 2, 2025 10:37 AM
Patented, Groundbreaking Blockchain for Public Companies 'BlackStar Digital Trading PlatformTM' can Facilitate U.S. Registered Securities to Trade on Blockchain Without Tokens. • BEGI • Jul 1, 2025 12:54 PM
UC Asset (UCASU) Public Offering's Acquisition Target Reported Better Results • UCASU • Jul 1, 2025 9:15 AM
One World Products, Inc. Appoints William Rowland as Chief Financial Officer • OWPC • Jul 1, 2025 9:14 AM
Envirotech Begins Delivery of Bumble Bee Electric School Bus Units with First Three Texas Orders • EVTV • Jul 1, 2025 9:01 AM